iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued to investors on Wednesday,RTT News reports. They currently have a $25.00 target price on the stock. Wedbush’s target price indicates a potential upside of 252.61% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Thursday, January 16th. Wells Fargo & Company decreased their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, December 19th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $7.09 on Wednesday. The company has a market capitalization of $259.03 million, a price-to-earnings ratio of -2.25 and a beta of 1.38. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75. The company’s fifty day moving average price is $7.53 and its two-hundred day moving average price is $9.54.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.13. As a group, analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current year.

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in iTeos Therapeutics during the 3rd quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of iTeos Therapeutics during the fourth quarter valued at $42,000. Virtus ETF Advisers LLC grew its position in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after acquiring an additional 3,293 shares during the last quarter. Forefront Analytics LLC acquired a new stake in shares of iTeos Therapeutics in the 4th quarter worth about $85,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of iTeos Therapeutics in the 4th quarter worth about $85,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.